Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

BioClin Therapeutics
130 Market Place, PMB 295
San Ramon, CA 94583
Phone: 925-413-6140
http://www.bioclintherapeutics.com/

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company's lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in the treatment of metastatic bladder cancer. The first clinical study is a Phase 1b/2 study of B-701 in combination with docetaxel. The study includes cohorts in which patients with FGFR3 mutation or fusion will be enrolled; patients will be administered B-701 plus docetaxel, or B-701 alone as monotherapy. The second study is evaluating the combination of B-701 and atezolizumab in mUC patients and will include those with overexpressed FGFR3 as well as those with FGFR3 mutation or fusion in their tumors. B-701 is also being tested in an on-going investigator sponsored study evaluating the combination of B-701 and pembrolizumab in mUC patients.

Key Contact
Name
Stephen Lau
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
03/22/17 $30,000,000 Series B HealthCap
Life Sciences Partners
Sofinnova Ventures
Tekla Capital Management
Ysios Capital
undisclosed